|
Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). |
|
|
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst) |
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Target Pharmasolutions (Inst); Tekmira (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Bristol-Myers Squibb |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Ono Pharmaceutical |
|
|
Honoraria - Bayer; Bracco Diagnostics; Bristol-Myers Squibb; Guerbet; Lilly; Meda Pharmaceuticals; Sirtex Medical |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Guerbet; Sirtex Medical |
Speakers' Bureau - Bayer; Bracco Diagnostics; Bristol-Myers Squibb; Guerbet; Lilly; Meda Pharmaceuticals; Sirtex Medical |
Research Funding - ArQule; Bayer; Bristol-Myers Squibb; Daiichi Sankyo |
Travel, Accommodations, Expenses - Bayer; Bracco Diagnostics; Guerbet; Lilly |
|
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; MSD Oncology; Novartis |
Speakers' Bureau - Amgen; Bayer; Eisai |
Research Funding - Novartis; Sirtex Medical |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb |
|
|
|
Stock and Other Ownership Interests - Exelixis |
|
|
|
Stock and Other Ownership Interests - Amgen; Exelixis; FibroGen |
Travel, Accommodations, Expenses - Exelixis |
|
|
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche |
Speakers' Bureau - Merrimack |
Research Funding - Astex Pharmaceuticals |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline |
|
|
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Merck Serono; Novartis; Ono Pharmaceutical; ONXEO |
Speakers' Bureau - Novartis |
Research Funding - Sanofi |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis |
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst) |
|
|
Consulting or Advisory Role - Agios; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb (I); CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Gilead Sciences (I); Halozyme; Halozyme (I); Inovio Pharmaceuticals; Ipsen; Medimmune; Merck Serono; Onxeo; PCI Biotech; Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; Vicus Therapeutics (I); Yakult Pharmaceutical |
Research Funding - Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Polaris |